HIT Consultant January 26, 2024
Jasmine Pennic

What You Should Know:

Deliberate AI, a digital health company harnessing AI to revolutionize mental health assessment, has secured a major milestone in its mission. The U.S. Food and Drug Administration (FDA) has selected Deliberate AI’s AI-generated Clinical Outcome Assessment (AI-COA™) for its Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.

– The collaboration between Deliberate AI and the FDA represents a giant leap in the fight against mental illness. By harnessing the power of AI, we can accelerate drug development, improve treatment efficacy, and ultimately empower patients to live healthier, happier lives

AI-COA™: A Beacon of Precision in Mental Health

Deliberate AI’s AI-COA™ leverages cutting-edge multimodal signal processing and machine learning to capture mental health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Digital Health, FDA, Govt Agencies, Mental Health, Provider, Technology
DeepSeek’s Ascent Means B2B Firms Need to Consider AI ROI
Using AI to reimagine telehealth with a fair, effective billing model
OpenAI Announces Deep Research Days After DeepSeek’s AI Earthquake
Harnessing AI to Transform Urgent Care Centers: Improving Efficiency, Morale, and Profitability
Samsung Doubles Down on AI and Smart Home Tech for 2025

Share This Article